Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2018
Lipocine Inc. (LPCN)
Last lipocine inc. earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.lipocine.com
Company Research
Source: PR Newswire
SALT LAKE CITY, Aug. 7, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30, 2018. Second Quarter and Recent Corporate HighlightsReceived a Complete Response Letter ("CRL") from the United States Food and Drug Administration ("FDA") regarding the New Drug Application ("NDA") for TLANDO™, the Company's oral testosterone product candidate for testosterone replacement therapy ("TRT") in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. Dosed the first subject in the ambulatory blood pressure ("ABPM") clinical study for TLANDO. This study is being conducted to definitively characterize TLANDO's blood pressure effect, if any, and is expected to address the blood pressure related concern cited in the FDA's Complete Response Letter. Completed a Post Action Meeting with the FDA on July 19th in which
Show less
Read more
Impact Snapshot
Event Time:
LPCN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LPCN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LPCN alerts
High impacting Lipocine Inc. news events
Weekly update
A roundup of the hottest topics
LPCN
News
- Lipocine Inc. (NASDAQ: LPCN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Cirrhosis Market and Pipeline Insights, 2024: Analysis of Emerging Drugs GXHPC 1 (GWOXI Stem Cell Applied Technology), LPCN 1148 (Lipocine), and Belapectin (Galectin Therapeutics) [Yahoo! Finance]Yahoo! Finance
- Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity [Yahoo! Finance]Yahoo! Finance
- Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityPR Newswire
- Lipocine Inc. (NASDAQ: LPCN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
LPCN
Earnings
- 11/8/23 - Miss
LPCN
Sec Filings
- 4/23/24 - Form S-3/A
- 4/23/24 - Form DEF
- 4/11/24 - Form 8-K
- LPCN's page on the SEC website